Batavia Biosciences releases ‘Amalia,’ a novel manufacturing facility in Leiden, The Netherlands, enhancing their capability in viral vaccine and vector production.
Batavia Biosciences has announced the launch of ‘Amalia,’ a new GMP-ready manufacturing facility in Bilthoven, Netherlands.
This facility marks a significant advancement in the company’s ability to produce viral vaccines and viral vectors for clinical manufacturing. Menzo Havenga, CEO of Batavia Biosciences, highlights that Amalia aligns with the company’s mission to bring medical solutions from the lab to patients, especially in the context of epidemic preparedness.
The facility, equipped with advanced technology and adhering to high-quality standards, is set to play a crucial role in vaccine and viral vector development and production.
Amalia is part of Batavia Biosciences’ broader expansion strategy, with further developments anticipated, including a larger facility in Leiden.
For more details and future updates from Batavia Biosciences, please refer to their official announcements.
The Faculty of Science at Leiden University is offering a new opportunity for professionals to deepen their knowledge of data-driven decision-making, complex systems, and...
𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟱 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻 𝘁𝗵𝗲𝗶𝗿 𝗱𝗼𝗼𝗿𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰? You get an Open Day that brings together over 2,400 visitors, families, students,...
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...